---
title: "Natera (NTRA) Receives a Buy from Morgan Stanley"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295407253.md"
description: "Morgan Stanley analyst Kallum Titchmarsh maintained a Buy rating on Natera (NTRA) with a $355 price target. Barclays also issued a Buy rating today, while Wells Fargo maintained a Hold rating as of August 7."
datetime: "2026-08-10T12:25:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295407253.md)
  - [en](https://longbridge.com/en/news/295407253.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295407253.md)
---

# Natera (NTRA) Receives a Buy from Morgan Stanley

Morgan Stanley analyst Kallum Titchmarsh maintained a Buy rating on Natera today and set a price target of $355.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Titchmarsh is a 4-star analyst with an average return of 9.1% and a 56.67% success rate. Titchmarsh covers the Healthcare sector, focusing on stocks such as Charles River Labs, 10x Genomics, and Danaher.

In addition to Morgan Stanley, Natera also received a Buy from Barclays’s Luke Sergott in a report issued today. However, on August 7, Wells Fargo maintained a Hold rating on Natera (NASDAQ: NTRA).

### Related Stocks

- [NTRA.US](https://longbridge.com/en/quote/NTRA.US.md)
- [MS.US](https://longbridge.com/en/quote/MS.US.md)
- [CRL.US](https://longbridge.com/en/quote/CRL.US.md)
- [TXG.US](https://longbridge.com/en/quote/TXG.US.md)
- [DHR.US](https://longbridge.com/en/quote/DHR.US.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)
- [WFC.US](https://longbridge.com/en/quote/WFC.US.md)
- [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md)
- [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md)
- [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md)
- [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md)
- [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md)
- [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md)
- [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md)
- [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md)
- [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md)
- [WFC-D.US](https://longbridge.com/en/quote/WFC-D.US.md)
- [WFC-L.US](https://longbridge.com/en/quote/WFC-L.US.md)
- [WFC-Y.US](https://longbridge.com/en/quote/WFC-Y.US.md)
- [WFC-C.US](https://longbridge.com/en/quote/WFC-C.US.md)
- [WFC-Z.US](https://longbridge.com/en/quote/WFC-Z.US.md)
- [WFC-A.US](https://longbridge.com/en/quote/WFC-A.US.md)

## Related News & Research

- [Natera (NTRA) Lands Kupando Trial Deal, Is The Upside Already Priced In?](https://longbridge.com/en/news/296016178.md)
- [GSA Capital Partners LLP Invests $3.08 Million in Natera, Inc. $NTRA](https://longbridge.com/en/news/296017646.md)
- [7,701 Shares in Natera, Inc. $NTRA Bought by Focus Partners Advisor Solutions LLC](https://longbridge.com/en/news/296017687.md)
- [Natera co-founder, Director Sheena Jonathan sells 6,000 shares worth $1.95 million](https://longbridge.com/en/news/295987218.md)
- [Natera partners with Kupando Therapeutics to use Latitude ctDNA test in Phase 1 skin cancer trial](https://longbridge.com/en/news/295645480.md)